Immunochemical analysis of dopamine transporter protein in Parkinson's disease

Annals of Neurology

Volumn 41, Issue 4, 1997, Pages 530-539

  Miller, Gary W ^a   Staley, Julie K ^b   Heilman, Craig J ^a   Ferez, Jeffrey T ^a   Mash, Deborah C ^b   Rye, David B ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; SENSITIVITY AND SPECIFICITY;

EID: 0030929663     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410417     Document Type: Article

References (45)

1. Hornykiewicz O, Kish SJ. Biochemical pathology of Parkinson's disease. Adv Neurol 1986;45:19-34
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880
3. Horn AS. Dopamine uptake: a review of progress in the last decade. Prog Neurobiol 1990;34:387-400
4. Shimada S, Kitayama S, Lin C-L, et al. Cloning and expression of a cocaine-sensitive dopamine transporter cDNA. Science 1991;254:576-578
5. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254:578-579
6. Giros B, El Mestikawy S, Godinot N, et al. Cloning, pharmacological characterization and chromosomal assignment of the human dopamine transporter. Mol Pharmacol 1992;42:383-390
7. Shimada S, Kitayama S, Walther D, Uhl G. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Mol Brain Res 1992;13:359-362
8. Blanchard V, Raisman-Vozari R, Vyas S, et al. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of rat mesencephalon. Mol Brain Res 1994;22:29-40
9. Uhl GR, Walther D, Mash D, et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35:494-498
10. 3H]-mazindol. Neuroscience 1992;49:317-327
11. Murray AM, Weihmueller FB, Marshall JF, et al. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;37:300-312
12. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease, J Neurochem 1987;49:617-621
13. Maloteux JM, Vanisberg MA, Laterre C, et al. [3H] GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988;156:331-340
14. Hirai M, Kitamura N, Hashimoto T, et al. [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 1988;47:237-243
15. Pearce RKB, Seeman P, Jellinger K, Tourtellotte WW. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol 1990;30(suppl 1):9-14
16. Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonism putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198
17. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298
18. Tedroff J, Aquilinius S-M, Laihinen A, et al. Striatal kinetics of 11C-(+)-nomifensine and 18F-fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 1990;81:24-30
19. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431
20. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49
21. Schoemaker H, Pimoule C, Arbilla S. Sodium dependent [3H] cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 1985;329:227-235
22. Pimoule C, Schoemaker H, Javoy-Agid F, et al. Decrease in [3H] cocaine binding to the dopamine transporter in Parkinson's disease. Eur J Pharmacol 1983;95:145-146
23. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-11969
24. Laihinen AO, Rinne JO, Nagren KA, et al. PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267
25. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598
26. Pristupa ZB, Wilson JM, HofTman BJ, et al. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H] WIN 35,428 and [3H] GBR 12,935 binding. Mol Pharmacol 1994;45:125-135
27. Boja JW, Markham L, Patel A, et al. Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. Neuroreport 1992;3:247-248
28. Gracz LM, Madras BK. [3H] WIN 34,428 ([3H]CFT) binds to multiple charge-states of the solubilized dopamine transporter in primate striatum. J Pharmacol Exp Ther 1995;273:1224-1234
29. Anderson PH, Aas Jansen JA, Nielsen EB. [3H] GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site. Eur J Pharmacol 1987;144:l-6
30. Rudnick G, Wall SC. Binding of the cocaine analog 2B-[3H] carbomethoxy-3B-(4-fluorophenyl)trropane to the serotonin transporter. Mol Pharmacol 1991;40:421-426
31. Wilson JM, Levey AI, Rajput A, et al. Comparison of different neurochemical estimates of striatal dopamine nerve terminal loss in idiopathic Parkinson's disease. Neurology 1996;46:718-726
32. Levey AI, Armstrong DB, Atwell SF, et al. Monoclonal antibodies to choline acetyltransferase: production, specificity, and immunohistochemistry. J Neurosci 1983;3:1-9
33. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15:17l4-1723
34. Levey AI, Hersch SM, Rye DB, et al. Localization of Dl and D dopamine receptors in brain with subtype specific antibodies. Proc Natl Acad Sci USA 1993;90:8861-8865
35. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
36. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354
37. Graybiel AM, Ragsdale WW, Yoneoka ES, Eide RP. An immunohistochemical study of enkephalins and other neuropeptides in the striatum of the cat with evidence that the opiate peptides are arranged to form mosaic patterns in register with the striosomal compartments visible by acetylcholinesterase staining. Neuroscience 1981;6:377-397
38. Goto S, Hirano A, Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology 1990;40:1051-1056
39. Nirenberg MJ, Vaughan RA, Uhl GR, et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996;16:436-447
40. Graybiel AM, Moratalla R, Quinn B, et al. Early stage loss of dopamine uptake-site binding in MPTP-treated monkeys. Adv Neurol 1993;60:34-39
41. Lynd-Balta E, Haber SN, The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 1994;59:625-640
42. Parent A, Lavoie B, Smith Y, Bedard P. The dopaminergic ni- gropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Adv Neurol 1990;53:111-116
43. Lindsay RM. Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 1994;15:249-251
44. Sakamoto S, Goto S, Ito H, Hirano A. Striosomal organization of substance P-like immunoreactivity in parkinsonian patients. Neurology 1992;42:1071-1075
45. Schneider JS, Rothblat DA, DiStefano L Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res 1994;643:86-91